Spark Therapeutics (ONCE) IPO Opens Up 96%

Today's IPO for Spark Therapeutics (NASDAQ: ONCE) opened for trading at $45.10 after pricing 7,000,000 shares of common stock at a public offering price of $23.00 per share, above the expected $19-$21 range.

J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as lead book-running managers for the offering. Cowen and Company, LLC is acting as lead manager and Sanford C. Bernstein & Co., LLC is acting as co-manager.

Spark is a late clinical-stage gene therapy company seeking to develop one-time, life-altering treatments for debilitating genetic diseases, with an initial focus on treating rare diseases. Spark's most advanced product candidate, SPK-RPE65, which has received both breakthrough therapy and orphan product designation, is in a fully-enrolled pivotal Phase 3 clinical trial for the treatment of a rare blinding condition. Spark also has product candidates in development for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases.

You May Also Be Interested In

• Singularity Future Technology closes $5M registered direct offering
• Elroy Air wins $46M U.S. Army contract for cargo drone system
• Kairos Pharma announces 1-for-7 reverse stock split